Acute Kidney Injury Following Treatment With CD19-Specific CAR T-Cell Therapy in Children, Adolescent, and Young Adult Patients With B-Cell Acute Lymphoblastic Leukemia
Source : https://pubmed.ncbi.nlm.nih.gov/38507119/
Frequent monitoring to facilitate early recognition and subsequent management of kidney complications after CD19-CAR T-cell therapy may reduce the severity of AKI in the CAYA patient population.
All episodes of AKI developed within the first 14 days after receiving CAR T-cell therapy and 50% of patients with AKI recovered kidney function to baseline within 30 days postinfusion.
In 644 adult survivors of childhood leukemia, severe sepsis during treatment was associated with significantly higher rates of moderate to severe neurocognitive dysfunction.
Australian Experience With Ibrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: a Study From the Lymphoma and Related Diseases Registry
Source : https://pubmed.ncbi.nlm.nih.gov/38376128/
Bruton's tyrosine kinase inhibitors (BTKi) have an established role in the management of patients with relapsed/refractory mantle cell lymphoma (MCL). However, scant data exist on outcomes of patients ineligible for...
Median progression-free and overall survival rates were 13.7 and 15.6 months, respectively, and were shorter in patients excluded from clinical trials based on ECOG PS ≥2.
Impact of Socioeconomic Disparities on Outcomes in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Source : https://www.nature.com/articles/s41375-024-02172-3
Racial and socioeconomic disparities impact outcomes after chemotherapy and limit access to allogeneic hematopoietic cell transplantation (HCT) in acute myeloid leukemia (AML), yet studies have yielded mixed results on the...
Despite a relatively racially homogenous cohort, Asian race was associated with improved nonrelapse mortality (HR 0.47), and American Indian/Alaskan Native race was associated with higher relapse risk.
Effect of Atorvastatin Versus Placebo on Efficacy in Patients With Diffuse Large B-Cell Lymphoma Receiving R-CHOP
Source : https://pubmed.ncbi.nlm.nih.gov/38380861/
STOP-CA was a multicenter, double-blind, randomized, placebo-controlled trial comparing atorvastatin to placebo in treatment-naïve lymphoma patients receiving anthracycline-based chemotherapy. We performed a preplanned subgroup to analyze the impact of atorvastatin...
Atorvastatin did not result in a statistically significant improvement in the complete response rate or progression-free survival, but both were numerically improved in the atorvastatin cohort.